肝脏特异性基因miR-122与肝脏疾病研究进展

作为肝脏特异性基因miRNA之一的miR-122,其与肝脏生理及病理过程有密切联系。它不仅可促进肝细胞分化,还可调控脂类代谢。对肝脏疾病,miR-122可通过慢性丙型肝炎病毒（HCV）基因5＇-UTR结合序列相互作用来促进HCV病毒复制,反之,亦可通过miR-122-cylin G1/p53-HBV调控路径抑制慢性乙型肝炎病毒（HBV）表达及复制过程。另外,miR-122可抑制肝细胞增殖过程及其恶性转化。值得注意的是,用于HCV慢性感染治疗的首个miR-122靶向药物已研究中。随着miR-122调控慢性肝炎、肝癌作用机制及影响肝功能发挥的研究逐渐被人们所认知,在慢性感染性疾病及肿瘤治疗中,其已成为一个重要且有效治疗途径。

Liver-specific gene miR-122 and liver diseases

miR-122 as one of the liver-specific genes,it links closely with liver physiological and pathological processes. It can not only promote hepatocytes differentiation, also can regulate lipid metabolism. For liver diseases,miR-122 may be combined with 5＇-UTR sequence of chronic hepatitis C virus（ HCV） gene to promote the replication of HCV,and it also can inhibit the expression and replication processes of chronic hepatitis B virus（ HBV） by miR-122-cylin G1 / p53-HBV signal pathway. In addition,miR-122 can inhibit the proliferation and malignant transformation of hepatocytes. It is worth noting that,the first miR-122 targeted drug which is for the treatment of chronic HCV infection have been studied. It is well known that miR-122 can regulate chronic hepatitis,hepatocellular carcinoma and liver function,which has become an important and effective therapeutic approach for chronic infectious diseases and tumors.